Patent · US Active

Amidoimidazopyridazines as MKNK-1 kinase inhibitors

US9745304B2 · kind B2 · utility

0Cited by

6References

9Claims

0Family size

Assignee

Bayer Pharma Aktiengesellschaft · DE

Inventors

Ludwig Zorn · Berlin, DE
Knut Eis · Berlin, DE
Volker Schulze · Hohen Neuendorf, DE
Detlev Sülzle · Berlin, DE
Florian Puehler · Wellesley, US
Philip Lienau · Berlin, DE
Ulf Bömer · Glienicke, DE
Kirstin Petersen · Berlin, DE
Andrea Hägebarth · Berlin, DE

Key dates

Filing date	Jan 28, 2014
Grant date	Aug 29, 2017
Priority date	—
Expiry date	Jan 28, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D491/048
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to amido-substituted imidazopyridazine compounds of general formula (I): in which A, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.